What does PHARMA MAR do?

PHARMA MAR is registered with the CBE as active in: Vervaardiging van farmaceutische grondstoffen. Private Limited, started on 5 August 2015, 2 establishments.

What is the address of PHARMA MAR?

The registered office of PHARMA MAR is located at Drukpersstraat 4, 1000 Brussel.

Is PHARMA MAR still active?

Yes. According to the CBE (31 October 2026) PHARMA MAR is active, legal situation “Normale toestand”, started on 5 August 2015.

Is PHARMA MAR registered on Peppol?

Yes, PHARMA MAR is registered on the Peppol network with ID 0208:0634863713.

What is the enterprise number of PHARMA MAR?

The enterprise number of PHARMA MAR is BE0634863713.

When was PHARMA MAR founded?

PHARMA MAR was founded on 5 August 2015.

Who are the directors of PHARMA MAR?

According to the 2025 annual accounts, the directors of PHARMA MAR are: Luis Mora Capitan, Elena Calleja Crespo.

Is PHARMA MAR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 August 2015; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did PHARMA MAR make in 2025?

PHARMA MAR posted a profit after taxes of € 8,208 in financial year 2025.

What is the revenue of PHARMA MAR?

As a small company, PHARMA MAR is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 654,069.

How much does an employee at PHARMA MAR earn?

The average wage cost per full-time employee at PHARMA MAR was € 136,600 in 2025: staff costs of € 532,895 for 3.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA MAR have?

According to the 2025 annual accounts, PHARMA MAR has 3.9 full-time equivalents (FTE).

PHARMA MAR (Private Limited) - Brussel - BE0634863713

Dossier PHARMA MAR, printed on 31 October 2026 from databakkes.be/en/0634863713/pharma-mar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 5.7 to 3.9.
Busy address KBO

50 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

PHARMA MAR from Brussel, company number BE0634863713, closed financial year 2025 with a result of € 8,208 after tax. For that financial year PHARMA MAR recorded a gross margin of € 654,069 and equity of € 223,426. Compared with financial year 2024, the result moved from € 5,870 to € 8,208. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 20, 2026.

What it is worth Growing

€ 223,426

▲ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 8,208

▲ 40% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 103,374

▼ 48% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 73,426.

People and assets in 2025

Full-time equivalents

3.9

▼ 0.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 532,895

▼ 12% vs 2024

€ 136,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,742

▼ 62% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 37,366

▲ 149% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 153,002

▼ 28% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 745,031 Gross margin 2022: € 745,031 First fiscal year in the series	€ 780,079 Gross margin 2023: € 780,079 ▲ 5% vs 2022 (€ 745,031) Favourable step	€ 694,671 Gross margin 2024: € 694,671 ▼ 11% vs 2023 (€ 780,079) Unfavourable step	€ 654,069 Gross margin 2025: € 654,069 ▼ 6% vs 2024 (€ 694,671) Unfavourable step	▼ 6%
Profit after taxes	€ 42,068 Profit after taxes 2022: € 42,068 First fiscal year in the series	€ -789 Profit after taxes 2023: € -789 ▼ € 42,857 vs 2022 (€ 42,068) Unfavourable step	€ 5,870 Profit after taxes 2024: € 5,870 ▲ € 6,659 vs 2023 (€ -789) Favourable step	€ 8,208 Profit after taxes 2025: € 8,208 ▲ 40% vs 2024 (€ 5,870) Favourable step	▲ 40%
Equity	€ 210,136 Equity 2022: € 210,136 First fiscal year in the series	€ 209,347 Equity 2023: € 209,347 Unchanged (€ 210,136) Unfavourable step	€ 215,217 Equity 2024: € 215,217 ▲ 3% vs 2023 (€ 209,347) Favourable step	€ 223,426 Equity 2025: € 223,426 ▲ 4% vs 2024 (€ 215,217) Favourable step	▲ 4%
Total debts	€ 782,776 Total debts 2022: € 782,776 First fiscal year in the series	€ 346,736 Total debts 2023: € 346,736 ▼ 56% vs 2022 (€ 782,776) Favourable step	€ 311,704 Total debts 2024: € 311,704 ▼ 10% vs 2023 (€ 346,736) Favourable step	€ 269,237 Total debts 2025: € 269,237 ▼ 14% vs 2024 (€ 311,704) Favourable step	▼ 14%
Cash	€ 238,760 Cash 2022: € 238,760 First fiscal year in the series	€ 208,648 Cash 2023: € 208,648 ▼ 13% vs 2022 (€ 238,760) Unfavourable step	€ 196,992 Cash 2024: € 196,992 ▼ 6% vs 2023 (€ 208,648) Unfavourable step	€ 103,374 Cash 2025: € 103,374 ▼ 48% vs 2024 (€ 196,992) Unfavourable step	▼ 48%
Retained profit	€ 60,136 Retained profit 2022: € 60,136 First fiscal year in the series	€ 59,347 Retained profit 2023: € 59,347 ▼ 1% vs 2022 (€ 60,136) Unfavourable step	€ 65,217 Retained profit 2024: € 65,217 ▲ 10% vs 2023 (€ 59,347) Favourable step	€ 73,426 Retained profit 2025: € 73,426 ▲ 13% vs 2024 (€ 65,217) Favourable step	▲ 13%
Balance sheet total	€ 992,913 Balance sheet total 2022: € 992,913 First fiscal year in the series	€ 556,083 Balance sheet total 2023: € 556,083 ▼ 44% vs 2022 (€ 992,913) Unchanged	€ 526,921 Balance sheet total 2024: € 526,921 ▼ 5% vs 2023 (€ 556,083) Unchanged	€ 492,662 Balance sheet total 2025: € 492,662 ▼ 7% vs 2024 (€ 526,921) Unchanged	▼ 7%
Employees (FTE)	6 Employees (FTE) 2022: 6 First fiscal year in the series	5.7 Employees (FTE) 2023: 5.7 ▼ 0.3 vs 2022 (6) Unchanged	4.3 Employees (FTE) 2024: 4.3 ▼ 1.4 vs 2023 (5.7) Unchanged	3.9 Employees (FTE) 2025: 3.9 ▼ 0.4 vs 2024 (4.3) Unchanged	▼ 0.4

Key figures of PHARMA MAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA MAR?

What happened at PHARMA MAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 20, 2026 New annual accounts for financial year 2025: profit of € 8,208 (▲ 40% vs 2024). Source: NBB ↗
2023 Luis Mora Capitan became a director. NBB
2023 Elena Calleja Crespo became a director. NBB
Nov 16, 2015 New establishment in Machelen (Brab.). KBO
Aug 5, 2015 New establishment in Brussel. KBO
Aug 5, 2015 Start of the company according to the CBE. KBO

In short

From € 42,068 profit in 2022 to € 8,208 profit in 2025.

Paid € 44,681 in corporate taxes since 2022.

Best year ever: 2022, with € 42,068 profit.

On average € 167,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Pharma Mar S.A. 100%

PHARMA MAR

Behind PHARMA MAR are Luis Mora Capitan and Elena Calleja Crespo. The shares are held by Pharma Mar S.A. (100%).

Directors

According to the 2025 annual accounts

Luis Mora Capitan

Director

since 2023

Elena Calleja Crespo

Director

since 2023

Shareholders

Pharma Mar S.A.

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Drukpersstraat 4

1000 Brussel

2.276.669.875

Leonardo da Vincilaan 19

1831 Machelen (Brab.)

Active since 16 November 2015

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 50 companies are registered at this address.

All companies at this address →

Grada

Société de Gestion patrimoniale et financière

€ 557,981 gross margin · 2026

Schalbroek

€ -20,347 gross margin · 2025

Immobilière du Boulevard

€ 31,024 gross margin · 2025

Société anonyme belge de la Forêt du Paular

€ -93,395 gross margin · 2025

+45 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0634.863.713

VAT number

BE 0634.863.713

Registered office

Drukpersstraat 4, 1000 Brussel

Names & denominations

PHARMA MAR

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

5 August 2015

Peppol

Active · Active since 27 Mar 2025

Activities · NACE

Vervaardiging van farmaceutische grondstoffen

Vervaardiging van overige farmaceutische producten

Groothandel in farmaceutische en medische artikelen

Activiteiten van reclamebureaus

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA MAR

Warning lights

Financials

What happened to PHARMA MAR?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions